Gastroenterology Week
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Gastroenterology Week
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Business Update
XOMA to receive royalties from bacterial production license for macular degeneration drug
August 7th, 2006
XOMA Ltd. (XOMA) announced that Lucentis, owned by Genentech, Inc. (DNA) and recently approved by the U.S. Food and Drug Administration (FDA) for the treatment of neovascular (wet) age-related macular degeneration, is the first marketed therapeutic product by a licensee of XOMA's bacterial cell expression (BCE) technology. XOMA will receive a royalty on worldwide sales of Lucentis. Another drug, Cimzia (certolizumab pegol, CDP870), owned by UCB (Euronext-Brussels:UCB), has been submitted to the FDA and European regulators for approval in Crohn disease and is currently in phase 3 clinical trials for rheumatoid arthritis. A pioneer in therapeutic...
Source: Gastroenterology Week (2006-08-07)
|
